IP diligence summaries
IP diligence summaries for investors, boards, and acquirers
Investors and diligence
Investors and acquirers need to know whether the IP story is real, owned, defensible, and commercially relevant. V24 turns filings, ownership, risk, and opportunity into clear decision material.
High-intent searches
Priorities
V24 connects technical protection with commercial timing, investor expectations, and competitor movement.
IP diligence summaries for investors, boards, and acquirers
Ownership, assignment, disclosure, and filing-risk review points
Portfolio strength, gap, and opportunity assessment
Post-investment IP roadmap and prosecution priorities
Relevant packages
Most sector matters begin with a focused sprint, an investor pack, competitive intelligence, or a global filing roadmap.
A focused route for founders who need a first patent application filed with speed, clarity, and attorney judgement.
Ideal for startups filing their first serious protection.
A board and investor-ready package that explains what is protected, what is pending, what is exposed, and what should happen next.
Ideal before seed, Series A, venture debt, grant, or acquisition conversations.
Ongoing patent, trade mark, design, prosecution, and portfolio management for companies moving beyond ad hoc filings.
Ideal for scaleups and leadership teams with multiple product lines.
A practical intelligence layer that turns patent data, competitor filings, and landscape signals into business decisions.
Ideal for companies comparing V24 with analytics-only platforms.
Related sectors
Innovation portfolios often cross technical boundaries.
AI and software
Patent, trade mark, data, and portfolio strategy for AI, SaaS, machine learning, automation, and software-enabled companies.
Hardware and deep tech
IP strategy for hardware, electronics, semiconductors, devices, sensors, embedded systems, and manufacturing innovation.
Medtech and life sciences
Patent and portfolio strategy for medical technology, diagnostics, devices, biotech-enabled platforms, and health innovation.
Next step
Talk to V24 about the filings, risks, competitors, and commercial milestones that matter most.